Search Results
Your search for The ASCO matches 21401 pages
Showing 4401 - 4450Expert Point of View: Benoit Rousseau, MD, PhD
Benoit Rousseau, MD, PhD, of Memorial Sloan Kettering Cancer Center, New York, called the findings of the phase II GERCOR NIPICOL trial “interesting and convincing.” Long-term follow-up showed the 3-year progression-free survival rate to be 70% after 1 total year of treatment with nivolumab plus...
Expert Point of View: Samuel J. Klempner, MD
Samuel J. Klempner, MD, Associate Professor at Massachusetts General Hospital and Harvard Medical School, commented on the NEONIPIGA study for The ASCO Post. “This study was the first prospective data set to show what many have suspected—that neoadjuvant immune checkpoint blockade would lead to a...
NIPICOL Trial: Promising Outcomes With Shorter Duration of Checkpoint Inhibition in Metastatic Colorectal Cancer
The phase II GERCOR NIPICOL study evaluated 1 year of treatment with nivolumab plus ipilimumab in patients with chemotherapy-resistant metastatic colorectal cancer whose tumors were microsatellite instability–high (MSI-H) or mismatch repair–deficient (dMMR). With this shortened treatment duration,...
Sotorasib in Previously Treated Patients With KRAS G12C–Mutant Colorectal Cancer
In a prespecified analysis of the phase II CodeBreaK100 trial reported in The Lancet Oncology, Marwan Fakih, MD, and colleagues found that the KRAS G12C protein inhibitor sotorasib showed modest activity in patients with previously treated KRAS G12C–mutant colorectal cancer.1 Study Details The...
Neoadjuvant Checkpoint Inhibitor Doublet Yields Complete Responses in Gastroesophageal Cancers
In patients with resectable microsatellite instability–high (MSI-H)/mismatch repair–deficient (dMMR) gastric and gastroesophageal junction adenocarcinoma, dual checkpoint inhibition with ipilimumab and nivolumab given as neoadjuvant therapy led to a pathologic complete response rate of 58.6%,...
Adding Pembrolizumab to Chemotherapy Improves Overall and Progression-Free Survival in First-Line Treatment of Advanced Esophageal Cancer
As reported in The Lancet by Jong-Mu Sun, MD, of Samsung Medical Center, Sungkyunkwan University, Seoul, and colleagues, an interim analysis in the phase III KEYNOTE-590 trial has shown that the addition of first-line pembrolizumab to chemotherapy resulted in improved overall and progression-free...
Expert Point of View: Elena Élez, MD, PhD
Invited discussant of the two studies, Elena Élez, MD, PhD, of the Colon Cancer Program, Vall d’Hebron Institute of Oncology, Barcelona, Spain, discussed the challenge of treating BRAF-mutant colorectal cancer and what the new data bring to that effort. Dr. Élez noted: “BRAF V600E–mutant...
Adding First-Line Nivolumab to Chemotherapy Improves Survival in Gastric, Gastroesophageal Junction, and Esophageal Adenocarcinomas
As reported in The Lancet by Yelena Y. Janjigian, MD, of the Gastrointestinal Oncology Service, Memorial Sloan Kettering Cancer Center, and colleagues, the phase III CheckMate 649 trial has shown that the addition of first-line nivolumab to chemotherapy resulted in improved overall and...
BRAF-Mutant Colorectal Cancer: Latest Findings for Targeted Treatment
The phase II ANCHOR CRC study, the largest prospective study of BRAF inhibitor–based therapy as first-line treatment of metastatic colorectal cancer, has met its primary endpoint, with 47.8% of patients with metastatic colorectal cancer responding to first-line treatment with encorafenib,...
Addition of Neoadjuvant FOLFIRINOX to Preoperative Chemoradiotherapy in Locally Advanced Rectal Cancer
As reported in The Lancet Oncology by Thierry Conroy, MD, and colleagues, the French phase III UNICANCER-PRODIGE 23 trial has shown that intensification of preoperative therapy with FOLFIRINOX (oxaliplatin, irinotecan, leucovorin, fluorouracil [5-FU]) prior to chemoradiotherapy resulted in...
New ASCO-SNO Guideline Addresses Treatment Recommendations Tailored to Glioma Subtypes
Reflecting recent significant classification changes and new data on the use of biomarkers to inform treatment for central nervous system tumors, a new guideline offers oncologists up-to-date recommendations for managing gliomas in adults with neurologic cancer.1 “Over the past decade, there have...
Most Favored Nation Model’s Withdrawal Complete; ASCO Applauds Decision Preserving Access to Care
On December 29, 2021, the Centers for Medicare & Medicaid Services (CMS) issued a final rule rescinding the Most Favored Nation (MFN) model. MFN was originally proposed in November 2020 and scheduled to be implemented on January 1, 2021. ASCO and other groups strenuously opposed what would have ...
ASCO Provisional Clinical Opinion Offers Guidance for Using and Interpreting Genomic Testing in Patients With Advanced Cancer
Somatic genomic testing should be a routine part of clinical care for many patients with metastatic or advanced solid tumors, according to a new ASCO provisional clinical opinion.1 As reported in the Journal of Clinical Oncology, the expert panel found that genomic testing in oncology practice has...
Should Patients Aged 80 and Older Receive Single-Agent Immune Checkpoint Inhibitor Treatment?
The checkpoint inhibitors are among the most important advances in oncology in recent times. They have changed the natural history of many tumors, particularly melanoma. They have a favorable toxicity profile, which for most patients is manageable and tolerable. However, there are several...
Expert Point of View: Quynh-Thu Le, MD, FACR, FASTRO
According to Quynh-Thu Le, MD, FACR, FASTRO, Professor and Chair of Radiation Oncology at Stanford, these results suggest that monitoring circulating human papillomavirus (HPV) DNA may lead to the detection of relapse prior to imaging. In an interview with The ASCO Post, Dr. Le also noted that...
Blood Test Predicts Recurrence of HPV-Driven Oropharyngeal Cancer After Treatment
A blood-basedliquid biopsy may accurately predict recurrence of human papillomavirus (HPV)-driven oropharyngeal squamous cell carcinoma following treatment, according to data presented at the 2022 Multidisciplinary Head and Neck Cancers Symposium.1 Results of the large, multi-institutional study...
American Cancer Society Names Arif Kamal, MD, First Chief Patient Officer
The American Cancer Society (ACS) has named Arif Kamal, MD, MBA, MHS, FACP, FAAHPM, FASCO, as its first Chief Patient Officer to lead its patient support vision and strategic plans to improve the lives of patients with cancer and their families. Based in Chapel Hill, North Carolina, Dr. Kamal will ...
I Enrolled in the WISDOM Study and Learned I Am at High Risk for Cancer
I have always been interested in volunteering my services and helping others, so when I got an e-mail asking if I’d like to participate in the WISDOM (Women Informed to Screen Depending on Measures of Risk) study (www.thewisdomstudy.org) I signed on. The study plans to enroll 100,000 diverse women...
New Role for Raymond N. DuBois, MD, PhD, FAACR, at The Mark Foundation for Cancer Research
Raymond N. DuBois, MD, PhD, FAACR, was recently appointed Executive Chairman of the Board of The Mark Foundation for Cancer Research. Dr. DuBois is Director of the Medical University of South Carolina (MUSC) Hollings Cancer Center and Distinguished University Professor at MUSC. As The Mark...
Robert Otto Valdez, PhD, MHSA, Named Director of the AHRQ
Robert Otto Valdez, PhD, MHSA, was appointed Director of the Agency for Healthcare Research and Quality (AHRQ) in February 2022. He was previously the Robert Wood Johnson Foundation (RWJF) Professor Emeritus of Family & Community Medicine and Economics at the University of New Mexico (UNM). In...
Expert Point of View: Quynh-Thu Le, MD, FACR, FASTRO
In an interview with The ASCO Post, Quynh-Thu Le, MD, FACR, FASTRO, Professor and Chair of Radiation Oncology at Stanford Cancer Center, called this phase II de-escalation trial an “intriguing study” that heads in the right direction for treatment de-escalation. However, Dr. Le noted, the...
ACCC Appoints David R. Penberthy, MD, MBA, as New President
David R. Penberthy, MD, MBA, was recently named President of the Association of Community Cancer Centers (ACCC) at the organization’s 48th Annual Meeting and Cancer Center Business Summit. Oncology professionals from around the nation gathered at the conference to discuss the convergence of...
New Appointments for ECOG-ACRIN and NCI Committees
Janice Mehnert, MD, was recently named Co-Chair of the ECOG-ACRIN Melanoma Committee, replacing Craig L. Slingluff, MD. Dr. Mehnert is Associate Director for Clinical Research and Director, Melanoma and Cutaneous Medical Oncology at NYU Langone’s Perlmutter Cancer Center. She specializes in both...
Allogeneic Transplantation for Hematologic Neoplasms in Adults
“The value of experience is not in seeing much, but in seeing wisely.” —Sir William Osler To complement The ASCO Post’s continued comprehensive coverage of the 2021 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting...
Arul Chinnaiyan, MD, PhD, Awarded Sjöberg Prize for Cancer Research
The Royal Swedish Academy of Sciences, which also awards Nobel Prizes, has announced the winner of the 2022 Sjöberg Prize. Arul Chinnaiyan, MD, PhD, S.P. Hicks Professor of Pathology and Urology at Michigan Medicine, is being honored for the discovery of recurrent gene fusions in prostate cancer....
Expert Point of View: E. Gabriela Chiorean, MD
The invited discussant of the CodeBreaK 100 data, E. Gabriela Chiorean, MD, Professor of Medicine at the University of Washington and Fred Hutchinson Cancer Research Center, and Clinical Director of the Gastrointestinal Medical Oncology program at Seattle Cancer Care Alliance, found the efficacy...
Peptide Receptor Radionuclide Therapy for Gastroenteropancreatic Neuroendocrine Tumors: Implications for Current Practice
The rising incidence and prevalence of gastroenteropancreatic endocrine tumors make them the second-most prevalent gastrointestinal cancer.1 Although most of these tumors are relatively slow growing, their histologic grade and differentiation are closely correlated with their clinical behavior.2,3...
ACCC Welcomes Matt Devino, MPH, as Director, Cancer Care Delivery and Health Policy
The Association of Community Cancer Centers (ACCC) announced that Matt Devino, MPH, has joined the organization as Director, Cancer Care Delivery and Health Policy. Mr. Devino will lead the organization’s initiatives to improve cancer care delivery and promote health equity across rural, urban,...
CodeBreaK 100: Sotorasib Shows Activity in KRAS G12C–Mutated Pancreatic Cancer
Promising activity in metastatic pancreatic cancer was shown by sotorasib, an inhibitor of the KRAS G12C mutation, in the phase I/II CodeBreaK 100 study presented by John H. Strickler, MD, Associate Professor of Medicine at Duke University Medical Center in Durham, North Carolina, during the...
Atezolizumab Induces Responses in Advanced Penile Cancer, but Biomarkers Needed to Improve Patient Selection
Use of the immune checkpoint inhibitor atezolizumab with or without radiotherapy showed antitumor activity in stage IV penile cancer in the phase II PERICLES trial, although the study failed to meet the primary endpoint of 1-year progression-free survival of at least 35%. The hints of activity were ...
ARIES Trial: Avelumab Failed to Improve 1-Year Survival in PD-L1–Positive Advanced Urothelial Cancer
First-line treatment with the PD-L1 antibody avelumab failed to meet the primary endpoint of an improvement in overall survival at 1 year for patients with cisplatin-ineligible, PD-L1–positive advanced urothelial cancer. However, the objective response and disease control rates were favorable in...
B.J. Rimel, MD, Named Medical Director, Cancer Clinical Trials Office
Gynecologic oncologist and surgeon B.J. Rimel, MD, recently was named Medical Director of the Cedars-Sinai Cancer Clinical Trials Office. She will serve as a medical liaison between clinical trial principal investigators and Cedars-Sinai Cancer leadership to ensure the quality of services provided...
KEYNOTE-564 Update Supports Benefit of Adjuvant Pembrolizumab in High-Risk Renal Cell Carcinoma
An updated analysis of the phase III KEYNOTE-564 trial continues to support the use of adjuvant pembrolizumab vs placebo in patients with renal cell carcinoma at high risk of recurrence, according to a presentation at the 2022 ASCO Genitourinary Cancers Symposium.1 At 30 months of follow-up,...
Expert Point of View: Elisabeth I. Heath, MD, FACP, and Oliver Sartor, MD
Formal discussant of the ARASENS trial, Elisabeth I. Heath, MD, FACP, Professor of Oncology and Associate Center Director, Translational Sciences, at Karmanos Cancer Institute in Detroit, commented on the changing paradigm in prostate cancer treatment. “The narrative is changing to triplet therapy, ...
Neoadjuvant Enfortumab Vedotin-ejfv Shows Activity in Muscle-Invasive Bladder Cancer
Neoadjuvant treatment with the antibody-drug conjugate enfortumab vedotin-ejfv achieved notable antitumor activity in patients with muscle-invasive bladder cancer who are ineligible for treatment with cisplatin, according to preliminary results for cohort H of the EV-103 trial reported at the 2022...
Study Reports Modest Gain in Progression-Free Survival With Continued Enzalutamide in Advanced Prostate Cancer
Enzalutamide is a common first-line choice for patients with metastatic castration-resistant prostate cancer, but response in some patients eventually wanes and then patients are switched to a different treatment. According to the phase IIIb PRESIDE trial, reported at the 2022 ASCO Genitourinary...
First-Line Olaparib Plus Abiraterone Extends Radiographic Progression-Free Survival in Men With Metastatic Castration-Resistant Prostate Cancer
The PARP inhibitor olaparib in combination with abiraterone demonstrated a statistically significant and clinically meaningful improvement in radiographic progression-free survival vs current standard-of-care abiraterone as a first-line treatment for patients with metastatic castration-resistant...
ASCO Stands With Ukraine’s Cancer Community
On March 2, 2022, ASCO issued the following statement: “ASCO stands with our Ukrainian members, the worldwide oncology community, and health-care providers around the globe in condemning Russia’s unprovoked war on Ukraine. We call for an immediate cessation of these hostilities and demand full...
Xin Gao, MD, on Prostate Cancer: Early-Phase Results on Bavdegalutamide
Xin Gao, MD, of Massachusetts General Hospital, discusses phase I/II findings on bavdegalutamide, an androgen receptor protein degrader, which showed clinical activity in heavily pretreated patients with metastatic castration-resistant prostate cancer who received one to two prior novel hormonal...
Triplet Combination Improves Overall Survival in Metastatic Hormone-Sensitive Prostate Cancer
Triplet therapy with the oral androgen receptor inhibitor darolutamide plus docetaxel plus androgen-deprivation therapy significantly improved overall survival in patients with metastatic hormone-sensitive prostate cancer vs docetaxel plus androgen-deprivation therapy, according to results of the...
The University of Texas MD Anderson Cancer Center Launches James P. Allison Institute
Today, The University of Texas MD Anderson Cancer Center launched the James P. Allison Institute, a visionary research and innovation hub within MD Anderson designed to foster groundbreaking science, to develop new treatments, and to bring the benefits of immunotherapy to all patients. The Allison...
CheckMate 9ER: Final Results Support First-Line Regimen of Nivolumab Plus Cabozantinib in Advanced Kidney Cancer
The combination of nivolumab plus cabozantinib achieved a continued survival benefit compared with sunitinib in patients with untreated clear cell metastatic or advanced renal cell carcinoma, according to a final overall survival analysis of the phase III CheckMate 9ER trial.1 Additionally,...
Study Identifies Genetic Variants That May Contribute to Accelerated Aging in Childhood Cancer Survivors
Scientists from St. Jude Children’s Research Hospital have identified variants in two genes that may be associated with accelerated aging in childhood cancer survivors. Their research looked at the difference between the survivors’ biologic age and chronologic age. The study, published by Dong et...
FDA Approves Radioligand for Metastatic Castration-Resistant Prostate Cancer
On March 23, the U.S. Food and Drug Administration approved lutetium Lu-177 vipivotide tetraxetan (Pluvicto) for the treatment of adult patients with prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer who have been treated with androgen receptor...
Tanya B. Dorff, MD, on Prostate Cancer: Early Data on PSCA-Targeted CAR T-Cell Therapy
Tanya B. Dorff, MD, of City of Hope National Medical Center, discusses the first-in-human phase I findings showing that prostate stem cell antigen (PSCA) CAR T-cell therapy is feasible in patients with metastatic castration-resistant prostate cancer, with preliminary antitumor activity exhibited.
Neil E. Fleshner, MD, MPH, on High-Risk Prostate Cancer: New Data on Abiraterone and Cabazitaxel
Neil E. Fleshner, MD, MPH, of the Princess Margaret Cancer Centre, discusses phase II results from the ACDC-RP trial, which indicate a significant tumor response to neoadjuvant abiraterone acetate plus prednisone and leuprolide, with or without cabazitaxel, in patients with high-risk prostate...
HRR Mutational Status May Be Prognostic of Survival Outcomes for Women With Recurrent Platinum-Sensitive Ovarian Cancer
Results of a biomarker analysis of the NRG Oncology NRG-GY004 trial were presented during the Society for Gynecologic Oncology’s (SGO) Annual Meeting on Women’s Cancer. The analysis, which occurred as part of a preplanned translational endpoint for the study, concluded that homologous recombination ...
Younger Patients With Appendicitis May Be at Increased Risk for Appendiceal Cancer
Although appendectomy is still the most effective treatment for acute appendicitis, nonoperative management is increasingly common, as recent studies—such as one published in November 2020 in The New England Journal of Medicine and a second published in December 2021 in the same journal—have shown...
Sequencing of Drug Combinations Could Amplify Antitumor Immune Response in Liver Cancer
A new therapeutic strategy for hepatocellular carcinoma (HCC) that initially primes the tumor with an immune checkpoint inhibitor before using a multikinase inhibitor has shown efficacy in a study published in the Journal of the National Cancer Institute. Kikuchi et al reported that the new...
Sue S. Yom, MD, PhD, on Thyroid Cancer: Expert Perspective on the State of the Field
Sue S. Yom, MD, PhD, of the University of California, San Francisco, discusses some of the latest developments in thyroid cancer, including the mutational landscape, therapies for high-risk and anaplastic diseases, and multimodalities for aggressive differentiated thyroid cancers.
